Printer Friendly

WARNER-LAMBERT'S ACE INHIBITOR ACCUPRIL APPROVED FOR U.S. MARKETING FOR TREATMENT OF HYPERTENSION

WARNER-LAMBERT'S ACE INHIBITOR ACCUPRIL APPROVED FOR U.S. MARKETING
 FOR TREATMENT OF HYPERTENSION
 MORRIS PLAINS, N.J., Nov. 20 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) said today that its cardiovascular drug Accupril (quinapril hydrochloride tablets), an angiotensin converting enzyme (ACE) inhibitor, has been approved in the United States for the treatment of hypertension. The drug will be marketed by the company's Parke-Davis division.
 Accupril is now approved for marketing in 38 countries worldwide for the treatment of hypertension.
 Accupril is well-tolerated and can be used to treat hypertension with once-a-day therapy for most patients. It is a potent inhibitor of angiotensin converting enzyme, a naturally occurring substance in the body. If left unchecked, ACE produces angiotensin II, a powerful vasoconstrictor.
 ACE inhibitors comprise the fastest growing segment among antihypertensive therapies. Sales of ACE inhibitors in the U.S. during 1991 are expected to exceed $1.5 billion. ACE inhibitors, whose share of the antihypertensive market has grown an average of 30 percent in each of the last five years, are increasingly being considered for initial use in treating hypertension.
 An estimated 60 million Americans have hypertension, or high blood pressure, putting them at risk of such complications as stroke and myocardial infarction. Only about 14 million people have their condition under control through medication. Patient compliance is a major problem. Patients find that the side effects of many antihypertensive therapies are more troublesome than their symptomless disease. ACE inhibitors have fewer side effects than other classes of antihypertensives, making it more likely that patients will continue their therapy on a long-term basis. Because Accupril can be used once- a-day for most patients, it is expected to enhance patient compliance.
 Parke-Davis is a leader in the treatment of cardiovascular disease. Among its products in this therapeutic category are the cholesterol- regulator Lopid (gemfibrozil), the antianginal Nitrostat (nitroglycerin) and Procan SR (procainamide hydrochloride), an antiarrhythmic.
 Warner-Lambert is a worldwide company devoted to developing, manufacturing and marketing quality health care and consumer products. It employs approximately 35,000 people.
 -0- 11/20/91
 /Peter Wolf, 201-540-6696, or Sandy Bell, 201-540-2145, both of Warner-Lambert/
 (WLA) CO: Warner-Lambert Company ST: New Jersey IN: MTC SU: SH -- NY061 -- 5485 11/20/91 13:55 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:368
Previous Article:FOUNDER LEAVES SYNERNETICS
Next Article:JAMAICAN RESEARCHERS GIVE GREEN LIGHT TO HUMAN CLINICAL TRIALS FOR PROMISING PLANT-BASED AIDS DRUG DEVELOPED IN SWITZERLAND
Topics:


Related Articles
PARKE-DAVIS OFFERS SINGLE AGENT COMMITMENT PROGRAM FOR NEW HYPERTENSION THERAPY
WARNER-LAMBERT ACHIEVES RECORD SALES; RAISES DIVIDEND 16 PERCENT
WARNER-LAMBERT'S ACCUPRIL CLEARED FOR TREATMENT OF HEART FAILURE
WARNER-LAMBERT TO RESTRUCTURE, TAKE ONE-TIME $327 MILLION CHARGE
WARNER-LAMBERT REPORTS SECOND-QUARTER SALES AND EARNINGS
10% PBT, 6% EPS GAINS REPORTED BY WARNER-LAMBERT FOR FIRST-QUARTER
Warner-Lambert, Sankyo Announce Joint Venture Partnership and Co-Promotion Agreement
Warner-Lambert Reports Fourth Quarter, Full-Year Sales And Earnings
Pfizer and Warner-Lambert Agree to $90 Billion Merger Creating the World's Fastest-Growing Major Pharmaceutical Company.
Pfizer Expects to Complete Acquisition of Warner-Lambert Expeditiously, McKinnell Tells Analyst Group.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters